ASTRO, Congress Urge CMS to Adjust Radiation Oncology APM
Congressional leaders from both political parties issued a series of oversight letters to the Centers for Medicare and Medicaid Services in recent months that implored the agency to amend its proposed radiation oncology advanced alternative payment model.
Cost-Effectiveness of Adjuvant Therapy in Early-Stage HER2-Positive Breast Cancer
The addition of neratinib after adjuvant trastuzumab is not projected to be cost-effective for patients with HER2-positive breast cancer, according to an analysis of the results of a phase III trial.
FDA Approves Zanubrutinib for Previously Treated MCL
On November 14, 2019, the Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa; BeiGene USA) for the treatment of adults with mantle cell lymphoma who received ≥1 prior therapies.
Budget Impact Analysis of Adjuvant Combination Therapy for Type of Melanoma
A new study evaluated the budget impact of dabrafenib plus trametinib for adjuvant treatment of patient with BRAF V600 mutation-positive, advanced melanoma from a US commercial payer perspective.
Immunotherapy Adoption in the Community for Melanoma Treatment
Adoption of immunotherapy for metastatic melanoma varies widely across US hospitals, suggesting inequity in access to these therapies, according to a recent study.
ASCO Launches Update to the Patient-Centered Oncology Payment Model
The American Society of Clinical Oncology announced today that it is rolling out a major update to its Patient-Centered Oncology Payment model – an alternative payment model designed to support transformation in cancer care delivery and reimbursement while providing patients with high-quality, high-value cancer care.
NCCN Publishes Updated Genetic Risk Assessment Recommendations
The National Comprehensive Cancer Network (NCCN) released updated genetic screening guidelines that feature emerging evidence on personalized medicine for patients with breast, ovarian, and pancreatic cancers.
